AMPH241115P65000
- 0.00
- 0.000.00%
Amphastar Pharmaceuticals Newsroom
Earnings Preview: AMPH to Report Financial Results Post-market on November 06
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024
Amphastar Pharmaceuticals: Strong Product Pipeline and Financial Position Justify Buy Rating
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Is Going Strong: Is the Market Following Fundamentals?
Is Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) The Top Stock With Improving Technical Ratings According To Piper Sandler?
Amphastar Pharmaceuticals (NASDAQ:AMPH) Could Easily Take On More Debt
Implied Volatility Surging for Amphastar Pharmaceuticals (AMPH) Stock Options
Amphastar Pharmaceuticals' (NASDAQ:AMPH) Three-year Earnings Growth Trails the Stellar Shareholder Returns
Insider Sale: Director Floyd Petersen Sells Shares of Amphastar Pharmaceuticals Inc (AMPH)
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio
Express News | Amphastar Pharmaceuticals: Armstrong, Genreach to Collaborate to Expand Distribution of Co’s Inhalation Product, Primatene Mist in Mainland China
Express News | Amphastar Pharmaceuticals: On Aug 28 Armstrong Pharmaceuticals & Hong Kong Genreach Limited Entered Into Distribution Agreement
Amphastar Pharmaceuticals to Present at the 2024 Wells Fargo Healthcare Conference
'Bottom-fishing' Ideas Within Piper Sandler's Universe of Stocks
Stocks With Three Weeks of Improving Technicals by Piper Sandler
Capital One Financial Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $70
Amphastar Pharmaceuticals Poised for Growth: Strong Product Performance and Strategic Financial Health Drive Buy Rating
Amphastar Pharmaceuticals Insider Sold Shares Worth $736,550, According to a Recent SEC Filing